Strativa Pharmaceuticals has entered into an agreement with Swedish Orphan Biovitrum (Sobi) for the development and commercialization of Nascobal cyanocobalamin (Vitamin B12) nasal spray in Europe. Sobi plans to begin development for European approval in early 2011 and will help to finance an upgrade of Strativa’s facilities necessary to meet EU regulations. QOL Medical, which had a pre-existing agreement with Sobi, sold worldwide rights for the product to Strativa in 2009. According to Strativa, Nascobal will be its first product marketed outside of the United States. Read the company’s press release.
European development deal for Strativa’s Nascobal
published on
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
